Abstracts tagged "Crohn’s Disease"

Abstract Number: 1823 • 2019 ACR/ARP Annual Meeting
Magnetic Resonance Enterography as a Screening Tool to Detect Sacroiliitis in Crohn’s Disease: Association with Clinical and Endoscopic Markers of Crohn’s Disease Activity
Fardina Malik¹, Irvine Levine ², Gabrielle Castillo ¹, Brian Jaros ², Erin Alaia ¹, Justin Ream ², Jordan E. Axelrad ¹, David P. Hudesman ¹ and Jose Scher ³, ¹New York University School of Medicine, New York, NY, ²New York University School of Medicine, New York, ³Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY
Background/Purpose: Prevalence of sacroiliitis (SI) in Crohn’s disease (CD) varies widely (range 4% -39%), depending on criteria utilized to define the disease (e.g. inflammatory back…
Abstract Number: 367 • 2018 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease (IBD) Among Patients (Pts) with Other Chronic Inflammatory Diseases (CID) Treated with Interleukin-17a (IL-17a) or Phosphodiesterase 4 (PDE4) Inhibitors
Bruno Emond¹, Lorie A. Ellis², Soumya D Chakravarty³, Martin Ladouceur¹ and Patrick Lefebvre¹, ¹Analysis Group, Inc., Montréal, QC, Canada, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA
Background/Purpose: IBD is often associated with other CID, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and psoriasis (PsO). Newer biologic agents…
Abstract Number: 1866 • 2018 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis
Mark C. Genovese¹, Jean-Frederic Colombel², Amanda M. Gellett³, Wen Xu³ and Dana Hardin³, ¹Department of Medicine, Stanford University, Palo Alto, CA, ²Department of Gastroenterology, The Mount Sinai Hospital, New York, NY, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Increased incidence of IBD, such as Crohn’s disease (CD) and ulcerative colitis (UC), has been observed in patients (pts) with PsA or plaque psoriasis…
Abstract Number: 2514 • 2018 ACR/ARHP Annual Meeting
Development of a Subcutaneous Formulation of CT-P13 (Infliximab): Maintenance Subcutaneous Administration May Elicit Lower Immunogenicity Compared to Intravenous Treatment
Dae-Hyun Yoo¹, René Westhovens², S. Ben-Horin³, W. Reinisch⁴, S. Schreiber⁵, B.D. Ye⁶, Sang-Joon Lee⁷, J.H. Suh⁷ and M.R. Kim⁷, ¹Department of Rheumatology, Hospital for Rheumatic Diseases Hanyang University, Seoul, Korea, Republic of (South), ²Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ³University of Tel Aviv Sheba Medical Center, Tel-Hashomer, Israel, ⁴Medical University of Vienna, Vienna, Austria, ⁵University Hospital Schleswig-Holstein, Kiel, Germany, ⁶Department of Gastroenterology and Inflammatory Bowel Disease Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ⁷CELLTRION, Inc., Incheon, Korea, Republic of (South)
Background/Purpose: Intravenous (IV) use of CT-P13, an infliximab (INX) biosimilar, has resulted in comparable efficacy, safety and immunogenicity as innovator INX in various indications including…
Abstract Number: 2883 • 2018 ACR/ARHP Annual Meeting
Testing for Anti-Microbial Antibodies with Cross-Reactivity to Human Tissue in Autoimmune Diseases
Peilin Zhang, Lawrence Minardi, J. Todd Kuenstner and Stephen Zekan, PZM Diagnostics, LLC, Charleston, WV
Background/Purpose: Autoantibodies are defining features of autoimmune diseases. How and why the autoantibodies are produced and how these autoantibodies relate to pathogenesis is poorly understood.…
Abstract Number: 372 • 2017 ACR/ARHP Annual Meeting
Phenotype of Chronic Recurrent Multifocal Osteomyelitis in a Tertiary Referral Centre: The Great Ormond Street Hospital Experience
Kulsoom Riaz¹ and Sandrine Lacassagne², ¹Paediatric Rheumatology/Gastroenterology, Great Ormond Street Hospital, London, United Kingdom, ²Paediatric Rheumatology, Great Ormond Street Hospital, London, United Kingdom
Background/Purpose: Recurrent Multifocal Osteomyelitis (CRMO) is an aseptic inflammatory bone disease that typically affects the metaphases of the long bones. It affects children, adolescents and…
Abstract Number: 594 • 2017 ACR/ARHP Annual Meeting
Imaging Biomarkers in Crohn’s Associated Axial Spondyloarthritis
Fardina Malik¹, John A. Carrino², Madeline Epsten³, Ellen Scherl⁴, Stephanie Wichuk⁵, Ulrich Weber⁶, Susanne J Pedersen⁷, Joel Paschke⁸, Jackie Szymonifka³, Georg Kroeber⁹, Randy Longman⁴, Walter P. Maksymowych⁵ and Lisa A. Mandl³, ¹Rheumatology, Hospital For Special Surgery, New York, NY, ²Radiology, Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Gastroenterology, Weill Cornell Medical College, New York, NY, ⁵Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁷Copenhagen Center for Arthritis Research, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark, ⁸CARE Arthritis, Edmonton, AB, Canada, ⁹University of Southern Denmark, Odense, Denmark
Background/Purpose: Axial SpA has been reported in 4-16% of patients with Crohn's disease (CD). However, some plain radiograph or magnetic resonance imaging (MRI) studies in…
Abstract Number: 1047 • 2017 ACR/ARHP Annual Meeting
Cost-Effectiveness of Drug-Level Guided Adalimumab Dosing
Zara Izadi¹, Gabriela Schmajuk², Milena Gianfrancesco³, Laura Trupin⁴, Kashif Jafri⁵, Jinoos Yazdany⁴ and Dhruv Kazi⁶, ¹Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ²San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁵University of California, San Francisco, San Francisco, CA, ⁶Department of Medicine, University of California, San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, CA
Background/Purpose: Adalimumab (ADA) induces and maintains clinical remission in patients with rheumatoid arthritis (RA) and Crohn’s disease (CD) but is an expensive drug. Drug-level and…
Abstract Number: 2748 • 2017 ACR/ARHP Annual Meeting
Immunogenicity of Infliximab Among Patients with Behcet’s Syndrome: A Controlled Study
Sinem Nihal Esatoglu¹, Fatma Nihan Akkoc¹, Yesim Ozguler¹, Fatma Ozbakir², Okan Kadir Nohut², Dilsen Cevirgen³, Vedat Hamuryudan¹, Ibrahim Hatemi⁴, Aykut Ferhat Celik⁵, Hasan Yazici¹ and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Central Research Laboratory, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of and Rheumatology, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Immunogenicity of anti-TNFs has been recognized as an important problem that may cause loss of response and adverse events such as infusion reactions. We…
Abstract Number: 962 • 2016 ACR/ARHP Annual Meeting
No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies
Atul A. Deodhar¹, Stefan Schreiber², Kunal Gandhi³, Todd Fox⁴, Corine Gaillez⁴ and Chetan Karyekar³, ¹Oregon Health & Science University, Portland, OR, ²Christian-Albrechts-Universität Kiel, Kiel, Germany, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has been evaluated and approved for the treatment of moderate to severe psoriasis, active psoriatic arthritis (PsA)…
Abstract Number: 1726 • 2016 ACR/ARHP Annual Meeting
An Integrated Safety Data Analysis Across All Phase II and Phase III Clinical Programs for Ustekinumab in Psoriatic Arthritis, Crohn’s Disease, and Psoriasis
Lianne S. Gensler¹, Elizabeth C. Hsia², Christopher Gasink², Bruce Randazzo², Dennis Parenti³, Steve Fakharzadeh³, Kehzen L. Tang² and Soumya Chakravarty³, ¹Medicine/Rheumatology, UCSF, San Francisco, CA, ²Janssen Research & Development, LLC, Spring House, PA, ³Janssen Scientific Affairs, LLC, Horsham, PA
Background/Objective:Therapeutic decisions are based on efficacy, but clinicians need to consider medication safety in this process. Here, we report ustekinumab (UST) integrated safety data in…
Abstract Number: 906 • 2015 ACR/ARHP Annual Meeting
Distinct Expression of IL-36Î±, β, Î³ and Their Antagonists IL-36Ra and IL-38 in Psoriasis, Rheumatoid Arthritis and Crohn’s Disease
Marie-Astrid Boutet¹, Géraldine Bart², Jérôme Amiaud¹, Bénédicte Brulin³, Céline Charrier³, Franck Morel⁴, Jean-Claude Lecron⁴, Malvyne Rolli-Derkinderen⁵, Arnaud Boureille⁶, Cem Gabay⁷, Gaby Palmer⁸, Benoit Le Goff² and Frédéric Blanchard⁹, ¹Laboratoire de physiologie de la résorption osseuse, Inserm UMR 957, Nantes, France, ²Rheumatology, Nantes University Hospital, Nantes, France, ³Inserm UMR 957, Nantes, France, ⁴EA 4331, Poitiers, France, ⁵Inserm UMR 913, Nantes, France, ⁶Hepato-Gastroenterology Unit, Nantes University Hospital, Nantes, France, ⁷Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁸Geneva University Hospital, Geneva, Switzerland, ⁹Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Inserm UMR 957, Nantes, France
Background/Purpose: The IL-36 family of cytokines comprises three agonists, IL-36α, IL-36β and IL-36g, an antagonist IL-36Ra, as well as IL-38, another potential IL-36 inhibitor. IL-36…
Abstract Number: 2061 • 2015 ACR/ARHP Annual Meeting
Uncovering Crohn’s Disease in Patients with Spondyloarthropathies Using Videocapsule Endoscopy
Uri Kopylov¹, Craig Watts², Michael Starr^3,4, Serge Dionne⁵, Jamie Koenekoop⁵ and Ernest Seidman⁵, ¹Gastroenterolog, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Department of Rheumatology, McGill University and Montreal General Hospital, Sainte-Anne-de-Bellevue, QC, Canada, ³Rheumatology, McGill University, Montreal, QC, Canada, ⁴Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁵Gastroenterology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Inflammatory bowel disease (IBD) is clinically associated with spondylarthropathies (SpA) in 5-15% of cases. Protocol colonoscopic assessment demonstrated asymptomatic inflammation characteristic of Crohn’s disease…
Abstract Number: 610 • 2014 ACR/ARHP Annual Meeting
Functional Implications of the Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) Association with Ankylosing Spondylitis and Crohn’s Disease: Impact on the Unfolded Protein Response
Zhenbo Zhang¹, Francesco Ciccia², Kirby Yee³, Giuliana Guggino², Hasan Abdullah⁴, Ricardo Alessandro⁵, Stefania Raimondo⁵, Giovanni Triolo⁵ and Nigil Haroon^1,6,7, ¹Toronto Western Research Institute, Toronto, ON, Canada, ²Rheumatology Unit, University of Palermo, Palermo, Italy, ³McMaster University, Hamilton, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵University of Palermo, Palermo, Italy, ⁶Rheumatology, University Health Network, Toronto, ON, Canada, ⁷Medicine, Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) has found to be associated with AS and Crohn’s Disease (CD). The functional implications of this association have not…
Abstract Number: 2284 • 2014 ACR/ARHP Annual Meeting
Joint Involvement in Pediatric Crohn’s Disease Is Related to Higher Disease Activity and Worse Quality of Life
Beata Derfalvi^1,2, Gabor Bozsaki³, Doloresz Szabo³, Aron Cseh³, Katalin Eszter Muller³, Andras Arato³ and Gabor Veres³, ¹Pediatrics, Dalhousie University, Halifax, NS, Canada, ²2nd. Dept. of Pediatrics, Semmelweis University, Budapest, Hungary, ³1st. Dept. of Pediatrics, Semmelweis University, Budapest, Hungary
Background/Purpose: The incidence of arthritis and arthralgia in pediatric patients with Crohn's disease (CD) is reported to be 2–15% and 22%, respectively. The aim of our…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].